Efficacy and safety of belimumab versus rituximab for refractory immune thrombocytopenia in patients with connective tissue disease

Efficacy and safety of belimumab versus rituximab for refractory immune thrombocytopenia in patients with connective tissue disease

Objectives Immune thrombocytopenia (ITP) is a haematological manifestation secondary to connective tissue disease (CTD). Many patients with CTD–ITP are refractory to glucocorticoids (GCs) plus immunosuppressant agents (ISAs); rituximab (RTX) is the recommended second-line therapy. Belimumab (BLM) sh...

Full description

Saved in:
Bibliographic Details
Main Authors: Min Wang, Yudong Liu, Tong Li, Xuan Zhang, Ying Jiang, Xiaoxia Zuo, Xiangning Yuan
Format: Article
Language:English
Published: BMJ Publishing Group 2025-05-01
Series:Lupus Science and Medicine
Online Access:https://lupus.bmj.com/content/12/1/e001501.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items